OracleBio contributed to a Clinical R&D program for a global oncology company focused on precision oncology.
By utilising multiplex immunofluorescence (IF) and quantitative digital pathology, we supported the researchers in understanding lymphocyte composition within NSCLC tissue by providing quantitative analysis of LAG-3 +ve TIL subsets within tumour microenvironment and determining ratios of dual and triple +ve TIL subsets.
Click here to view the Case Study poster and learn more about the aim and outcome.
To find out more about OracleBio’s digital pathology services to support Immuno-oncology R&D, please click here.
To keep up to date with all OracleBio news and publications, please follow us on LinkedIn by clicking the button below: